Genetic basis of acute lymphoblastic leukemia

Journal of Clinical Oncology

Volumn 35, Issue 9, 2017, Pages 975-983

  Iacobucci, Ilaria ^a   Mullighan, Charles G ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DUX4 PROTEIN; PROTEIN; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; CHROMOSOME ABERRATION; CHROMOSOME REARRANGEMENT; GENE FUSION; GENETIC VARIABILITY; GENETICS; GENOMICS; HUMAN; LEUKEMIA RELAPSE; PRE B LYMPHOCYTE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; CHILD;

CHILD; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 85016232457     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.70.7836     Document Type: Review

References (70)

1. Roberts KG, Li Y, Payne-Turner D, et al: Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 371:1005-1015, 2014
2. Roberts KG, Gu Z, Payne-Turner D, et al: High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults. J Clin Oncol 35:394-401, 2017
3. Gu Z, Churchman ML, Roberts KG, et al: Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nat Commun 7:13331, 2016
4. Meyer C, Hofmann J, Burmeister T, et al: The MLL recombinome of acute leukemias in 2013. Leukemia 27:2165-2176, 2013
5. Andersson AK, Ma J, Wang J, et al: The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat Genet 47:330-337, 2015
6. Barber KE, Harrison CJ, Broadfield ZJ, et al: Molecular cytogenetic characterization of TCF3 (E2A)/19p13.3 rearrangements in B-cell precursor acute lymphoblastic leukemia. Genes Chromosomes Cancer 46:478-486, 2007
7. Burmeister T, Gökbuget N, Schwartz S, et al: Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemia. Haematologica 95:241-246, 2010
8. Jeha S, Pei D, Raimondi SC, et al: Increased risk for CNS relapse in pre-B cell leukemia with the t (1;19)/TCF3-PBX1. Leukemia 23:1406-1409, 2009
9. Inaba T, Roberts WM, Shapiro LH, et al: Fusion of the leucine zipper gene HLF to the E2A gene in human acute B-lineage leukemia. Science 257:531-534, 1992
10. Hunger SP: Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: Clinical features and molecular pathogenesis. Blood 87:1211-1224, 1996
11. Moorman AV, Robinson H, Schwab C, et al: Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: A comparison of the MRC ALL97/99 and UKALL2003 trials. J Clin Oncol 31:3389-3396, 2013
12. Nachman JB, Heerema NA, Sather H, et al: Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 110:1112-1115, 2007
13. Holmfeldt L, Wei L, Diaz-Flores E, et al: The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 45:242-252, 2013
14. Mullighan CG, Goorha S, Radtke I, et al: Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446:758-764, 2007
15. Mullighan CG, Miller CB, Radtke I, et al: BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453:110-114, 2008
16. Iacobucci I, Storlazzi CT, Cilloni D, et al: Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: On behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). Blood 114:2159-2167, 2009
17. Mullighan CG, Su X, Zhang J, et al: Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 360:470-480, 2009
18. Martinelli G, Iacobucci I, Storlazzi CT, et al: IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: A GIMEMA AL WP report. J Clin Oncol 27:5202-5207, 2009
19. Paulsson K, Lilljebjörn H, Biloglav A, et al: The genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia. Nat Genet 47:672-676, 2015
20. Arber DA, Orazi A, Hasserjian R, et al: The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391-2405, 2016
21. Den Boer ML, van Slegtenhorst M, De Menezes RX, et al: A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: A genome-wide classification study. Lancet Oncol 10:125-134, 2009
22. Roberts KG, Pei D, Campana D, et al: Outcomes of children with BCR-ABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J Clin Oncol 32:3012-3020, 2014
23. Iacobucci I, Li Y, Roberts KG, et al: Truncating erythropoietin receptor rearrangements in acute lymphoblastic leukemia. Cancer Cell 29:186-200, 2016
24. Yoda A, Yoda Y, Chiaretti S, et al: Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci USA 107:252-257, 2010
25. Russell LJ, Capasso M, Vater I, et al: Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood 114:2688-2698, 2009
26. Mullighan CG, Collins-Underwood JR, Phillips LA, et al: Rearrangement of CRLF2 in B-progenitorand Down syndrome-associated acute lymphoblastic leukemia. Nat Genet 41:1243-1246, 2009
27. Mullighan CG, Zhang J, Harvey RC, et al: JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA 106:9414-9418, 2009
28. Harvey RC, Mullighan CG, Chen IM, et al: Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 115:5312-5321, 2010
29. Cario G, Zimmermann M, Romey R, et al: Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood 115:5393-5397, 2010
30. Maude SL, Tasian SK, Vincent T, et al: Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood 120:3510-3518, 2012
31. Waibel M, Solomon VS, Knight DA, et al: Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors. Cell Reports 5:1047-1059, 2013
32. Roberts KG, Morin RD, Zhang J, et al: Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 22:153-166, 2012
33. Schwab C, Ryan SL, Chilton L, et al: EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): Genetic profile and clinical implications. Blood 127:2214-2218, 2016
34. Liu YF, Wang BY, Zhang WN, et al: Genomic profiling of adult and pediatric B-cell acute lymphoblastic leukemia. EBioMedicine 8:173-183, 2016
35. Yasuda T, Tsuzuki S, Kawazu M, et al: Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults. Nat Genet 48:569-574, 2016
36. Zhang J, McCastlain K, Yoshihara H, et al: Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nat Genet 48:1481-1489, 2016
37. Lilljebjörn H, Henningsson R, Hyrenius-Wittsten A, et al: Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia. Nat Commun 7:11790, 2016
38. Harvey RC, Mullighan CG, Wang X, et al: Identification of novel cluster groups in pediatric highrisk B-precursor acute lymphoblastic leukemia with gene expression profiling: Correlation with genomewide DNA copy number alterations, clinical characteristics, and outcome. Blood 116:4874-4884, 2010
39. Clappier E, Auclerc MF, Rapion J, et al: An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions. Leukemia 28:70-77, 2014
40. Suzuki K, Okuno Y, Kawashima N, et al: MEF2D-BCL9 fusion gene is associated with highrisk acute B-cell precursor lymphoblastic leukemia in adolescents. J Clin Oncol 34:3451-3459, 2016
41. Prima V, Hunger SP: Cooperative transformation by MEF2D/DAZAP1 and DAZAP1/MEF2D fusion proteins generated by the variant t (1;19) in acute lymphoblastic leukemia. Leukemia 21:2470-2475, 2007
42. Russell LJ, Enshaei A, Jones L, et al: IGH@ translocations are prevalent in teenagers and young adults with acute lymphoblastic leukemia and are associated with a poor outcome. J Clin Oncol 32:1453-1462, 2014
43. Dang J, Wei L, de Ridder J, et al: PAX5 is a tumor suppressor in mouse mutagenesis models of acute lymphoblastic leukemia. Blood 125:3609-3617, 2015
44. Ferrando AA, Neuberg DS, Staunton J, et al: Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 1:75-87, 2002
45. Durinck K, Goossens S, Peirs S, et al: Novel biological insights in T-cell acute lymphoblastic leukemia. Exp Hematol 43:625-639, 2015
46. Weng AP, Ferrando AA, Lee W, et al: Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306:269-271, 2004
47. Papayannidis C, DeAngelo DJ, Stock W, et al: A phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Blood Cancer J 5:e350, 2015
48. Roderick JE, Tesell J, Shultz LD, et al: c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood 123:1040-1050, 2014
49. Coustan-Smith E, Mullighan CG, Onciu M, et al: Early T-cell precursor leukaemia: A subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 10:147-156, 2009
50. Patrick K, Wade R, Goulden N, et al: Outcome for children and young people with early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol 166:421-424, 2014
51. Wood B, Winter S, Dunsmore K, et al: Patients with early T-cell precursor (ETP) acute lymphoblastic leukemia (ALL) have high levels of minimal residual disease (MRD) at the end of induction: A Children's Oncology Group (COG) study. Blood 114:9, 2009 (abstr)
52. Zhang J, Ding L, Holmfeldt L, et al: The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481:157-163, 2012
53. Maude SL, Dolai S, Delgado-Martin C, et al: Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood 125:1759-1767, 2015
54. Mansour MR, Abraham BJ, Anders L, et al: Oncogene regulation: An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science 346:1373-1377, 2014
55. Papaemmanuil E, Rapado I, Li Y, et al: RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. Nat Genet 46:116-125, 2014
56. Swaminathan S, Klemm L, Park E, et al: Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia. Nat Immunol 16:766-774, 2015
57. Kino T, Nordeen SK, Chrousos GP: Conditional modulation of glucocorticoid receptor activities by CREB-binding protein (CBP) and p300. J Steroid Biochem Mol Biol 70:15-25, 1999
58. Lambert JR, Nordeen SK: CBP recruitment and histone acetylation in differential gene induction by glucocorticoids and progestins. Mol Endocrinol 17:1085-1094, 2003
59. Mullighan CG, Zhang J, Kasper LH, et al: CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 471:235-239, 2011
60. Meyer JA, Wang J, Hogan LE, et al: Relapsespecific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat Genet 45:290-294, 2013
61. Tzoneva G, Perez-Garcia A, Carpenter Z, et al: Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nat Med 19:368-371, 2013
62. Ma X, Edmonson M, Yergeau D, et al: Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. Nat Commun 6:6604, 2015
63. Mullighan CG, Phillips LA, Su X, et al: Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322:1377-1380, 2008
64. Irving J, Matheson E, Minto L, et al: Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood 124:3420-3430, 2014
65. Zhang MY, Churpek JE, Keel SB, et al: Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. Nat Genet 47:180-185, 2015
66. Noetzli L, Lo RW, Lee-Sherick AB, et al: Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. Nat Genet 47:535-538, 2015
67. Shah S, Schrader KA, Waanders E, et al: A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat Genet 45:1226-1231, 2013
68. He J, Abdel-Wahab O, Nahas MK, et al: Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. Blood 127:3004-3014, 2016
69. Faham M, Zheng J, Moorhead M, et al: Deepsequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood 120:5173-5180, 2012
70. Qin H, Cho M, Haso W, et al: Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein. Blood 126:629-639, 2015